ascorbic-acid and Hearing-Loss--Sensorineural
ascorbic-acid has been researched along with Hearing-Loss--Sensorineural* in 6 studies
Trials
1 trial(s) available for ascorbic-acid and Hearing-Loss--Sensorineural
Article | Year |
---|---|
Vitamins A, C, and E and selenium in the treatment of idiopathic sudden sensorineural hearing loss.
This study evaluated the effectiveness of vitamins A, C, and E, with selenium, in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL). This was a prospective, controlled study performed at a tertiary teaching and research hospital. Over a 32-month period, patients were treated with either our standard ISSNHL treatment regimen plus vitamins A, C, and E and selenium (ACE+ group) or with only our standard ISSNHL treatment regimen (ACE- group). The demographics, additional symptoms, mean initial and final hearing levels, mean hearing gain, and recovery data were compared between the two groups. The ACE+ group, consisting of 70 (55.5 %) patients, received vitamin A (natural beta-carotene, 26,000 IU), vitamin C (ascorbic acid, 200 mg), vitamin E (d-alpha-tocopherol, 200 IU), and selenium (50 μg) twice daily for 30 days in addition to our ISSNHL treatment regimen: methylprednisolone at an initial dose of 1 mg/kg body weight per day, tapered over 14 days; Rheomacrodex(®) [(10 g of dextran and 0.9 g of NaCl)/100 ml] 500 ml daily for 5 days; Vastarel(®) 20-mg tablet (20 mg of trimetazidine dihydrochloride) three times daily for 30 days; and ten 60-min hyperbaric oxygen (HBO) sessions (2.5 absolute atmospheres of 100 % O2), once daily, starting the day of hospitalization. The ACE- group comprised 56 (44.4 %) patients, who received only our ISSNHL treatment regimen. The mean hearing gains were 36.2 ± 20.3 dB in the ACE+ group and 27.1 ± 20.6 dB in the ACE- group. The mean hearing gain rates were significantly higher in the ACE+ group than in the ACE- group (p = 0.014). Treatment with vitamins A, C, and E and selenium was effective in ISSNHL patients undergoing treatment with methylprednisolone, dextran, trimetazidine dihydrochloride, and HBO, and might be more effective when the initial hearing level is below 46 dB. Topics: Adult; Aged; Antioxidants; Ascorbic Acid; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Humans; Hyperbaric Oxygenation; Male; Middle Aged; Prospective Studies; Selenium; Treatment Outcome; Vitamin A; Vitamin E; Vitamins | 2015 |
Other Studies
5 other study(ies) available for ascorbic-acid and Hearing-Loss--Sensorineural
Article | Year |
---|---|
Is the time from the onset to the treatment a prognostic indicator for hearing recovery in idiopathic sudden sensorineural hearing loss?
This study aims to investigate whether the time from the onset of symptoms to the start of treatment is a prognostic indicator in patients with idiopathic sudden sensorineural hearing loss (ISSNHL).. In this study, 96 patients (58 males, 38 females; mean age 37.8±2.5 years; range 16 to 67 years) who were diagnosed with ISSNHL in our clinic between January 1992 and April 2010 were retrospectively analyzed. All patients were treated with dextran 40 (rheomacrodex), pentoxifyllin, vitamin B complex and vitamin C regimen over 10 days with hospitalization and bed rest. The patients were tested by pure-tone audiometry. Audiograms were obtained on alternate days and at the end of the treatment.. There was a complete recovery in 45 (60%) of 75 patients whose treatment was started in the first seven days, while a partial recovery was observed in 17 (22.66%) and no recovery was observed in 13 (17.33%). There was a complete recovery in two (9.52%) of 21 patients whose treatment was started after the eighth day, while a partial recovery was observed in seven (33.33%) and no recovery was observed in 12 (57.14%).. Our study results suggest that treatment outcomes are better in the patients presenting to hospital at an early stage of loss of hearing. Topics: Adolescent; Adult; Aged; Ascorbic Acid; Audiometry, Pure-Tone; Bed Rest; Dextrans; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Humans; Male; Middle Aged; Pentoxifylline; Plasma Substitutes; Prognosis; Recovery of Function; Retrospective Studies; Treatment Outcome; Vasodilator Agents; Vitamin B Complex; Vitamins; Young Adult | 2015 |
ACEMg supplementation ameliorates progressive Connexin 26 hearing loss in a child.
Mutations in the gene encoding Connexin 26 are the most common cause of genetic hearing loss. The hearing loss is typically stable but may be progressive. The reason for progression is unknown. Antioxidants have been associated with attenuation of hearing loss from other insults. One antioxidant regimen consists of beta-carotene (metabolized to vitamin A), vitamin C, vitamin E, and magnesium (ACEMg). We present a child with Connexin 26 related hearing loss who experienced progressive hearing loss over 7 years of observation. He was given ACEMg daily for 3 years, during which time his progressive hearing loss was ameliorated. Topics: Antioxidants; Ascorbic Acid; Audiometry, Pure-Tone; Child; Connexin 26; Connexins; Dietary Supplements; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Magnesium; Male; Severity of Illness Index; Treatment Outcome; Vitamin A; Vitamin E | 2014 |
Effects of antioxidants on auditory nerve function and survival in deafened guinea pigs.
Based on in vitro studies, it is hypothesized that neurotrophic factor deprivation following deafferentation elicits an oxidative state change in the deafferented neuron and the formation of free radicals that then signal cell death pathways. This pathway to cell death was tested in vivo by assessing the efficacy of antioxidants (AOs) to prevent degeneration of deafferented CNVIII spiral ganglion cells (SGCs) in deafened guinea pigs. Following destruction of sensory cells, guinea pigs were treated immediately with Trolox (a water soluble vitamin E analogue)+ascorbic acid (vitamin C) administered either locally, directly in the inner ear, or systemically. Electrical auditory brainstem response (EABR) thresholds were recorded to assess nerve function and showed a large increase following deafness. In treated animals EABR thresholds decreased and surviving SGCs were increased significantly compared to untreated animals. These results indicate that a change in oxidative state following deafferentation plays a role in nerve cell death and antioxidant therapy may rescue SGCs from deafferentation-induced degeneration. Topics: Animals; Antioxidants; Ascorbic Acid; Auditory Threshold; Cell Survival; Chromans; Cochlear Nerve; Deafness; Denervation; Evoked Potentials, Auditory, Brain Stem; Guinea Pigs; Hair Cells, Auditory; Hearing Loss, Sensorineural; Male; Neurons, Afferent; Neuroprotective Agents; Oxidative Stress; Spiral Ganglion; Treatment Outcome | 2007 |
Glutathione protection against gentamicin ototoxicity depends on nutritional status.
This study demonstrates that gentamicin ototoxicity depends on dietary factors and correlates with tissue glutathione levels. After 15 days of gentamicin injections (100 mg/kg/day s.c.) guinea pigs on a regular protein diet (18.5% protein) had an average hearing loss of 9 dB at 3 kHz, 31 dB at 8 kHz and 42 dB at 18 kHz. Guinea pigs on a 7% protein diet showed an increased hearing loss of 52 dB at 3 kHz, 63 dB at 8 kHz and 74 dB at 18 kHz. Supplementing the low protein diet with either essential or sulfur-containing amino acids did not protect against gentamicin ototoxicity. Glutathione levels in the cochlear sensory epithelium were decreased in animals on a low protein diet and could be restored to normal by oral administration of glutathione monoethyl ester (1.2 g/kg/day) in combination with vitamin C (100 mg/kg/day). Glutathione supplementation significantly reduced the magnitude of hearing loss in the low protein diet group at all frequencies (43 dB reduction at 3 kHz, 27 dB reduction at 8 kHz and 21 dB reduction at 18 kHz). In animals on a full protein diet, dietary glutathione neither increased cochlear glutathione levels nor attenuated hearing loss. Serum gentamicin levels did not differ between animals on the various diets with or without glutathione supplement. These results suggest that gentamicin toxicity and detoxifying mechanisms are affected by the metabolic state of the animal and the glutathione content of the tissue. Thus, compounds that could potentially protect against gentamicin ototoxicity may be more correctly assessed in animal models of deficient nutritional states in which endogenous detoxifying mechanisms are compromised. This animal model might also be more realistically related to the clinical situation of a critically ill patient receiving gentamicin treatment. Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Ascorbic Acid; Cochlea; Diet; Dietary Proteins; Disease Models, Animal; Drug Therapy, Combination; Epithelium; Evoked Potentials, Auditory, Brain Stem; Food, Fortified; Gentamicins; Glutathione; Guinea Pigs; Hearing Loss, Sensorineural; Injections, Subcutaneous; Male; Nutritional Status; Temporal Lobe; Vestibule, Labyrinth; Weight Gain | 1995 |
Citrus bioflavonoid, ascorbic acid and the B Vitamins in treatment of certain types of neurosensory deafness: preliminary report.
Topics: Ascorbic Acid; Citrus; Deafness; Flavonoids; Folic Acid; Hearing Loss, Sensorineural; Meniere Disease; Vitamin B Complex; Vitamins | 1962 |